Marker Therapeutics Statistics
Share Statistics
Marker Therapeutics has 11.31M
shares outstanding. The number of shares has increased by 20.07%
in one year.
| Shares Outstanding | 11.31M |
| Shares Change (YoY) | 20.07% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 0.83% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 109 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 197.18K, so 1.84% of the outstanding
shares have been sold short.
| Short Interest | 197.18K |
| Short % of Shares Out | 1.84% |
| Short % of Float | 2.39% |
| Short Ratio (days to cover) | 3.47 |
Valuation Ratios
The PE ratio is -2.6 and the forward
PE ratio is -0.61.
Marker Therapeutics's PEG ratio is
0.07.
| PE Ratio | -2.6 |
| Forward PE | -0.61 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Marker Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.36,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.36 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,318,216,000,000 |
| Profits Per Employee | $-2,146,263 |
| Employee Count | 5 |
| Asset Turnover | 0.3 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 49.95B |
| Effective Tax Rate | -0.47% |
Stock Price Statistics
The stock price has increased by -71.67% in the
last 52 weeks. The beta is 1.54, so Marker Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | -71.67% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 2.82 |
| Relative Strength Index (RSI) | 47.87 |
| Average Volume (20 Days) | 122,078 |
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 6,591.1B
and earned -10.73M
in profits. Earnings per share was -1.19.
| Revenue | 6,591.1B |
| Gross Profit | 6,591.1B |
| Operating Income | -11,118.4B |
| Net Income | -10.73M |
| EBITDA | -11,118.4B |
| EBIT | -4.53M |
| Earnings Per Share (EPS) | -1.19 |
Full Income StatementBalance Sheet
The company has 19.19M in cash and 0 in
debt, giving a net cash position of 19.19M.
| Cash & Cash Equivalents | 19.19M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -447,017.2B |
| Total Assets | 22,022.9B |
| Working Capital | 18,558.4B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10,910.3B
and capital expenditures 0, giving a free cash flow of -10,910.3B.
| Operating Cash Flow | -10,910.3B |
| Capital Expenditures | n/a |
| Free Cash Flow | -10,910.3B |
| FCF Per Share | -1214930.12 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -168.69% and 0%.
| Gross Margin | 100% |
| Operating Margin | -168.69% |
| Pretax Margin | -162.06% |
| Profit Margin | n/a |
| EBITDA Margin | -168.69% |
| EBIT Margin | -168.69% |
| FCF Margin | -165.53% |
